A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Nordson Corporation Acquires Fluortek, Inc.

Today (June 2, 2020) Nordson Corporation announced they acquired Fluortek, Inc., an Easton, Pennsylvania based precision plastic extrusion manufacturer that provides custom dimensioned tubing to the medical device industry.

“As Nordson MEDICAL continues to expand its differentiated product offerings, the acquisition of Fluortek enhances our ability to deliver critical components that enable our customers’ most complex medical device innovations. This offering further supports Nordson MEDICAL’s position as a leading full-service solution provider of component and device manufacturing capabilities for OEM’s across the interventional, minimally invasive and surgical medical device landscape,” said Jeffrey Pembroke, Executive Vice President, Nordson Advanced Technology Solutions.

Fluortek will become part of the Nordson MEDICAL product line within Nordson’s Advanced Technology Solutions segment. This acquisition builds on the company’s strategic objective to grow Nordson MEDICAL’s product offerings serving the medical device market.

“We are excited to welcome the Fluortek employees to the Nordson MEDICAL family,” continued Pembroke. “We look forward to integrating their precision extrusion expertise and enhancing our advanced components portfolio.”

The terms of the deal were not disclosed.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy